Tirzepatide

Research summary

Tirzepatide is a synthetic peptide acting as a dual agonist of the GIP and GLP-1 receptors. It has been studied extensively in randomized clinical trials and is FDA-approved under other brand names for specific indications —a regulatory fact noted for research-literature context.

In the SURMOUNT-1 Phase 3 trial, participants with obesity or overweight lost a mean of 15.0-20.9% of body weight at 72 weeks depending on dose, versus 3.1% on placebo, with the large majority of treated participants achieving at least 5% weight loss. Extended follow-up to 176 weeks found the weight loss was largely sustained. These figures come from supervised clinical trials of an approved pharmaceutical, not data describing unsupervised research use.

Sources: NEJM, 2022 (SURMOUNT-1). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.